Results 41 to 50 of about 44,621 (163)

Adoptive transfer of tumor specific T cells from allogeneic donors is feasible, effective and safe alternative to autologous T cell based tumor immunotherapy

Journal of Medical Science, 2014
Donor lymphocyte infusion is used to increase the graft versus tumor (GVT) effect after allogeneic hematopoietic cell transplant. The limited spectrum of activity and high risk of graft versus host disease (GVHD) remain major limitations of this approach.
Eliza P. Kwiatkowska-Borowczyk, Anna Kozłowska, Klaudia Maruszak, Luiza Kańczuga-Koda, Mariusz Koda, Monika Dajnowiec, Andrzej Mackiewicz, Dariusz W. Kowalczyk   +7 more
doaj   +1 more source

Cancer immunotherapies: advances and bottlenecks

Frontiers in Immunology, 2023
Immunotherapy has ushered in a new era in cancer treatment, and cancer immunotherapy continues to be rejuvenated. The clinical goal of cancer immunotherapy is to prime host immune system to provide passive or active immunity against malignant tumors ...
Rui Rui, Rui Rui, Rui Rui, Rui Rui, Liqun Zhou, Liqun Zhou, Liqun Zhou, Liqun Zhou, Shiming He, Shiming He, Shiming He, Shiming He   +11 more
doaj   +1 more source

Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting

Nature Communications, 2021
KRAS is commonly mutated at codon 12 in several cancer types, offering a unique opportunity for the development of neoantigen-targeted immunotherapy. Here the authors present a pipeline for the prediction, identification and validation of HLA class-I ...
Adham S. Bear, Tatiana Blanchard, Joseph Cesare, Michael J. Ford, Lee P. Richman, Chong Xu, Miren L. Baroja, Sarah McCuaig, Christina Costeas, Khatuna Gabunia, John Scholler, Avery D. Posey, Mark H. O’Hara, Anze Smole, Daniel J. Powell, Benjamin A. Garcia, Robert H. Vonderheide, Gerald P. Linette, Beatriz M. Carreno   +18 more
doaj   +1 more source

Adoptive T-Cell Immunotherapy [PDF]

, 2015
Epstein-Barr virus (EBV) is associated with a range of malignancies involving B cells, T cells, natural killer (NK) cells, epithelial cells, and smooth muscle. All of these are associated with the latent life cycles of EBV, but the pattern of latency-associated viral antigens expressed in tumor cells depends on the type of tumor.
Stephen, Gottschalk, Cliona M, Rooney
openaire   +2 more sources

NK-92 cells labeled with Fe3O4-PEG-CD56/Avastin@Ce6 nanoprobes for the targeted treatment and noninvasive therapeutic evaluation of breast cancer

Journal of Nanobiotechnology
Adoptive cellular immunotherapy as a promising and alternative cancer therapy platform is critical for future clinical applications. Natural killer (NK) cells have attracted attention as an important type of innate immune regulatory cells that can ...
Jingge Lian, Meng Li, Meng Duan, Yaqian Sun, Zilin Wang, Xinyu Guo, Jingchao Li, Guo Gao, Kangan Li   +8 more
doaj   +1 more source

Membrane protein trafficking in the anti-tumor immune response: work of endosomal-lysosomal system

Cancer Cell International, 2022
Immunotherapy has changed the treatment landscape for multiple cancer types. In the recent decade, great progress has been made in immunotherapy, including immune checkpoint inhibitors, adoptive T-cell therapy, and cancer vaccines. ICIs work by reversing
Yan Jin, Zhifeng Deng, Ting Zhu
doaj   +1 more source

Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment

Bioactive Materials
Adoptive immunotherapy, notably involving chimeric antigen receptor (CAR)-T cells, has obtained Food and Drug Administration (FDA) approval as a treatment for various hematological malignancies, demonstrating promising preclinical efficacy against ...
Yun Chang, Mingyang Chang, Xiaoping Bao, Cheng Dong   +3 more
doaj   +1 more source

Adoptive T cell therapy: Addressing challenges in cancer immunotherapy

Journal of Translational Medicine, 2005
Adoptive T cell therapy involves the ex vivo selection and expansion of effector cells for the treatment of patients with cancer. In this review, the advantages and limitations of using antigen-specific T cells are discussed in counterpoint to vaccine ...
Yee Cassian
doaj   +1 more source

Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies

Journal of Immunology Research, 2017
A significant proportion of hematological malignancies remain limited in treatment options. Immune system modulation serves as a promising therapeutic approach to eliminate malignant cells.
Baixin Ye, Creed M. Stary, Qingping Gao, Qiongyu Wang, Zhi Zeng, Zhihong Jian, Lijuan Gu, Xiaoxing Xiong   +7 more
doaj   +1 more source

Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities

Frontiers in Immunology, 2019
Cancer immunotherapy has been firmly established as a new milestone for cancer therapy, with the development of multiple immune cells as therapeutic tools.
Weilei Hu, Guosheng Wang, Dongsheng Huang, Dongsheng Huang, Meihua Sui, Meihua Sui, Yibing Xu   +6 more
doaj   +1 more source